Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase
inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical …

Background Some patients with severe asthma remain symptomatic and obstructed despite
maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic agent,
可能是一个有效的在这种patie支气管扩张剂nts. Objective We sought to compare the …

Background Asthma is a heterogeneous disease in which there is a differential response to
哮喘的治疗方法。这个heterogeneity needs to be evaluated so that a personalized
management approach can be provided. Objectives We stratified patients with moderate-to …

Objective. Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic
pulmonary fibrosis (IPF). The pathological pathways involved in fibrogenesis in IPF and
interstitial lung disease associated with systemic sclerosis (SSc-ILD) show commonalities; …

Interstitial lung disease is a common manifestation of systemic sclerosis. Systemic sclerosis–
associated interstitial lung disease is characterized by progressive pulmonary fibrosis and a
reduction in pulmonary function. Effective treatments for systemic sclerosis–associated …

Objective: We examined the efficacy and safety of nintedanib in Japanese patients with
systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the global Safety and
Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial. Methods: Randomised patients …

Abstract Background A Phase II, multicentre, randomised, double-blind, placebo-controlled,
crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV 1) time profile after 3
weeks' treatment with once-daily (QD) or twice-daily (BID) olodaterol (at the same total daily …

Background In patients with idiopathic pulmonary fibrosis (IPF), nintedanib has a
manageable adverse event (AE) profile characterised predominantly by gastrointestinal (GI)
events. The efficacy and safety of nintedanib versus placebo in patients with SSc-ILD were …

Background Olodaterol is a novel, inhaled long-acting β 2-agonist (LABA) with> 24-h
duration of action investigated in asthma and chronic obstructive pulmonary disease.
Methods Two multicentre studies examined the efficacy and safety of 4 weeks' once-daily …

Page 1. / Poster Discussion Session / Tuesday, May 22/8:15 AM-10:45 AM / Room 3010-3012
(West Building, C22 ASTHMA THERAPY Level 3), Moscone Center Dose-Finding Study Of
Once-Daily Treatment With Olodaterol, A Novel Long-Acting B2-Agonist, In Patients With Asthma …